摘要
目的:分析贝伐珠单抗联合奥拉帕利维持治疗对子宫内膜癌患者血清肿瘤标志物水平的影响。方法:采用随机数字表法将上海市第一人民医院蚌埠医院2023年4月—2024年7月收治的60例子宫内膜癌患者分为参照组30例与研究组30例。两组进行紫杉醇+卡铂一线化疗,参照组给予贝伐单抗维持治疗,研究组给予贝伐珠单抗+奥拉帕利维持治疗,两组维持治疗3个月。比较两组治疗总有效率、不良反应发生率,比较两组治疗前后的血清糖类抗原125(CA125)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)水平及原癌基因人类表皮生长因子受体2(c-erbB2)、髓细胞增生原癌基因(c-myc)表达量。结果:研究组治疗总有效率高于参照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。治疗后,研究组血清CA125、CEA、CA19-9水平低于参照组(P<0.05)。治疗后,研究组c-erbB2、c-myc表达量低于参照组(P<0.05)。结论:贝伐珠单抗联合奥拉帕利维持治疗可有效抑制子宫内膜癌患者原癌基因表达,降低血清肿瘤标记物水平,提高疗效,且无明显不良反应发生。
Objective:To analyze the clinical effect of Bevacizumab combined with Olaparib maintenance therapy on the levels of serum tumor markers in patients with endometrial cancer.Method:Sixty patients with endometrial cancer admitted to Shanghai First People's Hospital Bengbu Hospital from April 2023 to July 2024 were divided into a reference group of 30 cases and a study group of 30 cases by the random number table method.Both groups received first-line chemotherapy with Paclitaxel+Carboplatin.The reference group was given maintenance treatment with Bevacizumab,and the study group was given maintenance treatment with Bevacizumab+Olaparib.Both groups received maintenance treatment for 3 months.The total effective rate and adverse reaction incidence of the two groups were compared,and the serum carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)levels and the expression of proto-oncogene human epidermal growth factor receptor 2(c-erbB2)and myeloblast proliferative proto-oncogene(c-myc)before and after treatment were compared between the two groups.Result:The total effective rate of the study group was higher than that of the reference group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the serum levels of CA125,CEA,and CA19-9 in the study group were lower than those in the reference group(P<0.05).After treatment,the expression levels of c-erbB2 and c-myc in the study group were lower than those in the reference group(P<0.05).Conclusion:The Bevacizumab combined with Olaparib maintenance therapy can effectively inhibit the expression of proto-oncogenes in patients,reduce serum tumor marker levels,improve efficacy,and have no significant adverse reactions.
作者
王丹丹
肖成炜
WANG Dandan;XIAO Chengwei(Obstetrics and Gynecology Department of Shanghai First People's Hospital Bengbu Hospital,Bengbu 233002,China;不详)
出处
《中国医学创新》
2025年第36期53-57,共5页
Medical Innovation of China
基金
蚌埠医科大学科技项目自然科学重点项目(2023byzd106)。
